We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-20.62%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.84B
AUM Growth
-$1.19B
Cap. Flow
+$214M
Cap. Flow %
5.56%
Top 10 Hldgs %
54.93%
Holding
140
New
25
Increased
22
Reduced
18
Closed
27

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$104M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$59.7M
3
ZYME icon
Zymeworks
ZYME
+$47.4M
4
NVRO
NEVRO CORP.
NVRO
+$39.5M
5
BDTX icon
Black Diamond Therapeutics
BDTX
+$33.6M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$152M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$78.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$53.8M
4
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$37.3M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$23.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Financials 0.28%
3 Technology 0.27%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$3.61B
$13.4M 0.35%
495,000
+190,000
+62% +$5.3M
ESTA icon
52
Establishment Labs
ESTA
$2.71B
$13.3M 0.35%
922,633
-127,895
-12% -$2.82M
ALEC icon
53
Alector
ALEC
$169M
$12.3M 0.32%
511,731
– –
YMAB
54
DELISTED
Y-mAbs Therapeutics
YMAB
$12.1M 0.31%
522,480
-39,757
-7% -$1.15M
GILD icon
55
Gilead Sciences
GILD
$165B
$11.2M 0.29%
+1,500,000
New +$104M
CYPH
56
Cypherpunk Technologies Inc
CYPH
$64M
$10.6M 0.28%
+672,650
New +$13M
SDGR icon
57
Schrodinger
SDGR
$1.13B
$10.5M 0.27%
+250,000
New +$9.44M
TWST icon
58
Twist Bioscience
TWST
$5.32B
$10.4M 0.27%
322,356
+106,500
+49% +$2.86M
VCRA
59
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$10.3M 0.27%
470,000
+173,580
+59% +$3.95M
ATRC icon
60
AtriCure
ATRC
$2.08B
$10.2M 0.26%
+302,227
New +$10.9M
SCPE.U
61
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
$10M 0.26%
1,000,000
– –
MORF
62
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.54M 0.25%
650,000
– –
HCAT icon
63
Health Catalyst
HCAT
$160M
$8.38M 0.22%
328,698
+45,000
+16% +$1.37M
RVMD icon
64
Revolution Medicines
RVMD
$38.5B
$7.82M 0.2%
+350,000
New +$9.69M
ALDX icon
65
Aldeyra Therapeutics
ALDX
$97.1M
$7.62M 0.2%
3,085,458
– –
IMVTU
66
DELISTED
Immunovant, Inc. Units
IMVTU
$7.36M 0.19%
400,000
– –
FULC icon
67
Fulcrum Therapeutics
FULC
$241M
$7.16M 0.19%
600,000
– –
ANAB icon
68
AnaptysBio
ANAB
$1.54B
$7.07M 0.18%
500,000
-500,000
-50% -$7.58M
CERN
69
DELISTED
Cerner Corp
CERN
$6.75M 0.18%
105,000
– –
SILK
70
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.64M 0.17%
+204,600
New +$8.19M
VTRS icon
71
Viatris
VTRS
$20.8B
$6.03M 0.16%
+400,000
New +$7.66M
VRAY
72
DELISTED
ViewRay, Inc.
VRAY
$5.71M 0.15%
2,451,748
– –
NGNE icon
73
Neurogene
NGNE
$672M
$5.54M 0.14%
25,000
– –
VERU icon
74
Veru
VERU
$35.5M
$5.4M 0.14%
165,000
– –
TBIO
75
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$4.99M 0.13%
435,000
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2020 Portfolio in Review

As of Q1 2020, Perceptive Advisors held 140 positions worth $3.84B, down 24% from $5.03B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors deployed $214M of net new capital in Q1 2020, opening 25 new positions and adding to 22 existing holdings. Its largest new stake was Gilead Sciences: 1,500,000 shares worth $11.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Momenta Pharmaceuticals, Inc., an estimated $78.1M trimmed.

  • Perceptive Advisors's largest Q1 2020 buy was Gilead Sciences: 1,500,000 shares worth $11.2M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2020, an estimated $59.7M increase.
  • Perceptive Advisors's biggest Q1 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $78.1M.
  • Perceptive Advisors fully exited Amarin Corp in Q1 2020, selling an estimated $152M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $3.84B portfolio in Q1 2020.
  • Perceptive Advisors opened 25 new positions and closed 27 in Q1 2020.
  • Perceptive Advisors's portfolio value fell 24% quarter-over-quarter to $3.84B.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.